Community Schedule

You are currently viewing May 2024

2 results showing for: 'haemophilus influenzae type b vaccine'

Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type B vaccine

Inj 30 IU diphtheria toxoid with 40 IU tetanus toxoid, 25 mcg pertussis toxoid, 25 mcg pertussis filamentous haemagglutinin, 8 mcg pertactin, 80 D-Ag U polio virus, 10 mcg hepatitis B surface antigen in 0.5 ml syringe
- Brand Fully subsidised brand. Infanrix-hexa
- Pharmacode2459396
- Subsidy $0.00
- Measure / Qty per 10

Only on a prescription
No patient co-payment payable
1. Funded for children meeting any of the following criteria
  1. Up to four doses for children up to and under the age of 10 for primary immunisation; or
  2. An additional four doses (as appropriate) are funded for (re-)immunisation for children up to and under the age of 10 who are patients post haematopoietic stem cell transplantation, or chemotherapy; pre or post splenectomy; pre- or post solid organ transplant, renal dialysis and other severely immunosuppressive regimens; or
  3. Up to five doses for children up to and under the age of 10 receiving solid organ transplantation.
2. Contractors will be entitled to claim payment from the Funder for the supply of Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type b vaccine to people eligible under the above criteria pursuant to their contract with Health New Zealand (Health NZ) for subsidised immunisation, and they may only do so in respect of the Diphtheria, tetanus, pertussis, polio, hepatitis B and haemophilus influenzae type b vaccine listed in the Pharmaceutical Schedule.
3. Contractors may only claim for populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraph A above.

Note: A course of up-to four vaccines is funded for catch up programmes for children (up to and under the age of 10 years) to complete full primary immunisation. Please refer to the Immunisation Handbook for the appropriate schedule for catch up programmes.

Haemophilus influenzae type B vaccine

Haemophilus Influenzae type B polysaccharide 10 mcg conjugated to tetanus toxoid as carrier protein 20-40 mcg; prefilled syringe plus vial 0.5 ml
- Brand Fully subsidised brand. Hiberix
- Pharmacode2087758
- Subsidy $0.00
- Measure / Qty per 1

Only on a prescription
No patient co-payment payable
1. One dose for people meeting any of the following:
  1. For primary vaccination in children; or
  2. An additional dose (as appropriate) is funded for (re-)immunisation for people post haematopoietic stem cell transplantation, or chemotherapy; functional asplenic; pre or post splenectomy; pre- or post solid organ transplant, pre or post cochlear implants, renal dialysis and other severely immunosuppressive regimens; or
  3. For use in testing for primary immunodeficiency diseases, on the recommendation of an internal medicine physician or paediatrician.
2. Contractors will be entitled to claim payment from the Funder for the supply of Haemophilus influenzae type b vaccine to people eligible under the above criteria pursuant to their contract with Health New Zealand (Health NZ) for subsidised immunisation, and they may only do so in respect of the Haemophilus influenzae type b vaccine listed in the Pharmaceutical Schedule.
3. Contractors may only claim for populations within the criteria that are covered by their contract, which may be a sub-set of the population described in paragraph A above.

Rectangle page icon symoblising a PDF. PDF
A tick icon. Fully subsidised
An oval with the number 29 in it. Unapproved medicine under Section 29
An asterisk symbol. 3 or 6 months should be dispensed at once
Two duplicate pages icon. Click to copy
A triangle symbol. Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.
OP Original pack
Sole Subsidised Supply